Oxidative stress and cardiovascular disease

Canadian Journal of Cardiology

Volumn 13, Issue 11, 1997, Pages 1021-1025

  Hoeschen, Robert J ^a,b  

^a UNIVERSITY OF MANITOBA   (Canada)

^b ST BONIFACE GENERAL HOSPITAL   (Canada)

Author keywords

Antioxidant therapy; Oxidative stress

Indexed keywords

ANTIOXIDANT;

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; HEART FAILURE; HUMAN; OXIDATIVE STRESS; PATHOGENESIS; SHORT SURVEY; THROMBOCYTE AGGREGATION; VASCULAR ENDOTHELIUM;

ANTIOXIDANTS; ARTERIOSCLEROSIS; CARDIOVASCULAR DISEASES; ENDOTHELIUM, VASCULAR; HEART FAILURE, CONGESTIVE; HUMANS; OXIDATIVE STRESS; PLATELET AGGREGATION;

EID: 0031437761     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (60)

1. Steinberg D. Oxidative modification of LDL and atherogenesis. Circulation 1997;95:1062-71.
2. Fret B. Reactive oxygen species and antioxidant vitamins: mechanisms of action. Am J Med 1994;97:3A5S-13S.
3. Rice-Evans C, Diplock AT. Current status of antioxidant therapy. Free Radic Biol Med 1993;15:77-96.
4. Singh N, Dhalla AK, Seneviratne C, Singal PK. Oxidative stress and heart failure. Mol Cell Biochem 1995;147:77-81.
5. Kloner RA, Przyklenk K, Whittaker P. Deleterious effects of oxygen radicals in ischermia/reperfusion. Circulation 1989;80:1115-23.
6. Caterine MR, Spencer KT, Pagan-Carlo LA, Smith RS, Buettner GR, Kerber RE. Direct current shocks to the heart generate free radicals: an electron paramagnetic resonance study. J Am Coll Cardiol 1996;28:1598-609.
7. Diaz-Velez CR, Garcia-Castineiras S, Mendoza-Ramos E, Hemandez-Lopez E. Increased malondialdchyde in peripheral blood of patients with congestive heart failure. Am Heart J 1996;131:146-52.
8. McMurray J, Chopra M, Abdullah I, Smith WE, Dargie HJ. Evidence of oxidative stress in chronic heart failure in humans. Eut Heart J 1993;14:1493-8.
9. Salonen JT, Nyyssonen K, Salonen R, et al. Lipoprotein oxidation and progression of carotid athersclerosis. Circulation 1997;95:840-5.
10. Jialal I, Grundy SM. Effect of combined supplementation with α-tocopherol, ascorbate, and beta carotene on low-density lipoprotein oxidation. Circulation 1993;88:2780-6.
11. 2-isoprostanes) in smokers. N Engl J Med 1995;332:1198-203.
12. Reilly M, Delanty N, Lawson JA, FitzGerald GA. Modulation of oxidant stress in vivo in chronic cigarette smokers. Circulation 1996;94:19-25.
13. Sobotka PA, Brottman MD, Weitz Z, Birnbaum AJ, Skosey JL, Zarling EJ. Elevated breath pentane in heart failure reduced by free radical scavenger. Free Radic Biol Med 1993;14:643-7.
14. Yla-Herttuala S, Palinski W, Rosenfeld ME, et al. Evidence for the presence of oxidatively modified low density lipoprotein in atherosclerotic lesions of rabbit and man. J Clin Invest 1989;84:1086-95.
15. Salonen JT, Yla-Herttuala, Yamamoto R, et al. Autoantibody against oxidised LDL and progression of carotid atherosclerosis. Lancet 1992;339:883-7.
16. Parthasarathy S, Khoo JC, Miller E, Bamett J, Witztum JL, Steinberg D. Low density lipoprotein rich in oleic acid is protected against oxidative modification: implications for dietary prevention of atherosclerosis. Proc Natl Acad Sci USA 1990;87:3894-8.
17. Reaven P. Dietary and pharmacologic regimens to reduce lipid peroxidation in non-insulin dependent diabetes mellitus. Am J Clin Nutr 1995;62:1483S-9S.
18. Shen GX, Novak C, Angel A. Effect of dietary vitamin E supplements on cholesteryl ester transfer activity in hamster adipose tissue. Atherosclerosis 1996;124:211-9.
19. Ishigami I, Yamashita S, Sakai N, et al. High-density lipoproteins from probucol-treated patients have increased capacity to promote cholesterol efflux from mouse peritoneal macrophages loaded with acetylated low-density lipoproteins, Eur J Clin Invest 1997;27:285-92
20. Rosenfeld ME. Oxidized LDL affects multiple atherogenic cellular responses. Circulation 1991;83:2137-40.
21. Khan BV, Parthasarathy SS, Alexander RW, Medford RM. Modified low density lipoprotein and its constituents augment cvtokine-activated vascular cell adhesion molecule-1 gene expression in human vascular endothelial cells, J Clin Invest 1995;95:1262-70.
22. Berliner JA, Navab M, Fogelman AM, et al. Atherosclerosis: basic mechanisms. Oxidation, inflammation and genetics. Circulation 1995;91:2488-96.
23. O'Brien KD, Alpers CE, Hokanson JE, Wang S, Chait A. Oxidatation-specific epitopes in human coronary atherosclerosis are not limited to oxidized low-density lipoprotein. Circulation 1996;94:1216-25.
24. Stringer MD, Gorog PG, Freeman A, Kakkar VV. Lipid peroxides and atherosclerosis. BMJ 1989;298:281-4.
25. Liu K, Cuddy TE, Pierce GN. Oxidative status of lipoproteins in coronary disease patients. Am Heart J 1992;123:285-90.
26. Chait A, Brazg R, Tribble DL, Krauss RM. Susceptibility of small, dense, low-densitv lipoproteins to oxidative modification in subjects with the atherogenic lipoprotein phenotype, pattern B. Am J Med 1993;94:350-6.
27. Kaneko M, Hayashi J, Saito I, Miyasaka N. Probucol downregulates E-selectin expression on cultured human vascular endothelial cells. Arterioscler Thromb Vase Biol 1996;16:1047-51.
28. McPherson R, Hogue M, Milne RW, Tall AR, Marcel YL. Increase in plasma cholesteryl ester transfer protein during probucol treatment: relation to changes in high density lipoprotein composition. Arterioscler Thromb 1991;11:476-81.
29. Jha P, Flather M, Lonn E, Farkouh M, Yusuf S. The antioxidant vitamins and cardiovascular disease: a critical review of epidemiologic and clinical trial data. Ann Intern Med 1995;123:860-72.
30. Olson RE. Vitamin E and its relation to heart disease. Circulation 1973;48:179-84.
31. Stephens NG, Parsons A, Schofield PM, et al. Randomised controlled trial of vitamin E in patients with coronary disease; Cambridge Heart Antioxidant Study (CHAOS). Lancet 1996;347:781-6.
32. Sebbag L, Forrat R, Canet E, Renaud S, Delaye J, deLorgeril M. Effects of dietary supplementation with alpha-tocopherol on myocardial infarct size and ventricular arrhythmias in a dog model of ischemia-reperfusion. J Am Coll Cardiol 1994;24:1580-5.
33. Santanam N, Parthasarathy S. Paradoxical actions of antioxidants in the oxidation of low density lipoprotein by peroxidases. J Clin Invest 1995;95:2540-600.
34. Rapola JM, Virtamo J, Ripatti S, et al. Randomised trial of α-tocopherol and β-carotene supplements on incidence of major coronary events in men with previous myocardial infarction. Lancet 1997;349:1715-20.
35. Traber MG, Packer L. Vitamin E: beyond antioxidant function. Am J Clin Nutr 1995;62:1501S-9S.
36. Chin JH, Azhar S, Hoffman BB. Inactivation of endothelial derived relaxing factor by oxidized lipoproteins. J Clin Invest 1992;89:10-8.
37. Galle J, Mulsch A, Busse R, Bassenge E. Effects of native and oxidized low density lipoproteins on formation and inactivation of endothelium-derived relaxing factor. Arterioscler Thromb 1991;11:198-203.
38. Selwyn AP, Kinlay S, Libby P, Ganz P. Atherogenic lipids, vascular dysfunction, and clinical signs of ischemic heart disease. Circulation 1997;95:5-7.
39. Heitzer T, Yla-Herttuala S, Luoma J, et al. Cigarette smoking potentiates endothelial dysfunction of forearm resistance vessels in patients with hypercholesterolemia: role of oxidized LDL. Circulation 1996;93:1346-53.
40. Anderson TJ, Meredith IT, Charbonneau F, et al. Endotheliumdependent coronary vasomotion relates to the susceptibility of LDL to oxidation in humans. Circulation 1996;93:1647-50.
41. Ting HH, Timimi FK, Boles KS, Creager SJ, Ganz P, Creager MA. Vitamin C improves endothelium-dependent vasodilation in patients with non-insulin-dependent diabetes mellitus. J Clin Invest 1996;97:22-8.
42. Heitzer T, Just H, Munzel T. Antioxidant vitamin C improves endothelial dysfunction in chronic smokers. Circulation 1996;94:6-9.
43. Gilligan DM, Sack MN, Guetta V, et al. Effect of antioxidant vitamins on low density lipoprotein oxidation and impaired endothelium-dependent vasodilation in patients with hypercholesterolemia. J Am Coll Cardiol 1994;24:1611-7.
44. Chen LY, Mehta P, Mehta JL. Oxidized LDL decreases L-arginine uptake and nitric oxide synthase protein expression in human platelets: relevance of the effect of oxidized LDL on platelet function. Circulation 1996;93:1740-6.
45. Leo R, Pratico D, Iuliano L, et al. Platelet activation by superoxide anion and hydroxyl radicals intrinsically generated by platelets that had undergone anoxia and then reoxygenated. Circulation 1997;95:885-91.
46. Freedman JE, Farhat JH, Loscalzo J, Keaney JF. α-tocopherol inhibits aggregation of human platelets by a protein kinase C-dependent mechanism. Circulation 1996;94:2434-40.
47. Massey KD, Burton KP. α-tocopherol attenuates myocardial membrane-related alterations resulting from ischemia and reperfusion. Am J Physiol 1989;256:H1192-9.
48. Lee V, Randhawa AK, Singal PK. Adriamycin-induced myocardial dysfunction in vitro is mediated by free radicals. Am J Physiol 1991;261:H989-95.
49. Siveski-Iliskovic N, Hill M, Chow DA, Singal PK. Probucol protects against adriamycin cardiomyopathy without interfering with its antitumor effect. Circulation 1995;91:10-5.
50. Hill MF, Singal PK. Antioxidant and oxidative stress changes during heart failure subsequent to myocardial infarction in rats. Am J Pathol 1996;148:291-300.
51. Rubinstein JD, Lesnefsky EJ, Byler RM, Fennessey PV, Horwitz LD. Trolox C, a lipid-soluble membrane protective agent, attenuates myocardial injury from ischemia and reperfusion. Free Radic Biol Med 1992;13:627-34.
52. Dhalla AK, Hill MF, Singal PK. Role of oxidative stress in transition of hypertrophy to heart failure. J Am Coll Cardiol 1996;28:506-14.
53. Blaustein AS, Schine L, Brooks WW, Fanburg BL, Bing OHL. Influence of exogenously generated oxidant species on myocardial function. Am J Physiol 1986;250:H595-9.
54. Klein HH, Pich S, Lindert-Heimberg S, Nebendahl K, Niedmann P. Failure of chronic, high-dose, oral vitamin E treatment to protect the ischemic, reperfused porcine heart. J Mol Cell Cardiol 1993;25:103-12.
55. Belch JJF, Bridges AB, Scott N, Chopra M. Oxygen free radicals and congestive heart failure. Br Heart J 1991;65:245-8.
56. 2a generation during coronary reperfusion. Circulation 1997;95:2492-9.
57. The HOPE study investigators. The HOPE (Heart Outcomes Prevention Evaluation) Study: The design of a large, simple randomized trial of an angiotensin-converting enzyme inhibitor (ramipril) and vitamin E in patients at high risk of cardiovascular events. Can J Cardiol 1996;12:127-37.
58. Packer M, Bristow MR, Cohn JN, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med 1996;334:1349-55.
59. Yue TL, Cheng HY, Lysko PG, et al. Carvedilol, a new vasodilator and beta adrenoceptor antagonist, is an oxidant and free radical scavenger. J Pharmacol Exp Ther 1992;263:92-8.
60. Feuerstein GZ, Ruffolo RR. Carvedilol, a novel vasodilating beta-blocker with the potential for cardiovascular organ protection. Eur Heart J 1996;17(Suppl B):24-9.